- Home
- FEMY vs HHS Comparison
FEMY vs HHS Comparison
Compare FEMY & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- HHS
- Stock Information
- Founded
- FEMY 2004
- HHS 1923
- Country
- FEMY United States
- HHS United States
- Employees
- FEMY N/A
- HHS N/A
- Industry
- FEMY Medical/Dental Instruments
- HHS Advertising
- Sector
- FEMY Health Care
- HHS Consumer Discretionary
- Exchange
- FEMY Nasdaq
- HHS Nasdaq
- Market Cap
- FEMY 29.9M
- HHS 28.4M
- IPO Year
- FEMY 2021
- HHS N/A
- Fundamental
- Price
- FEMY $0.87
- HHS $3.36
- Analyst Decision
- FEMY Strong Buy
- HHS
- Analyst Count
- FEMY 3
- HHS 0
- Target Price
- FEMY $8.67
- HHS N/A
- AVG Volume (30 Days)
- FEMY 274.9K
- HHS 29.9K
- Earning Date
- FEMY 08-07-2025
- HHS 08-07-2025
- Dividend Yield
- FEMY N/A
- HHS N/A
- EPS Growth
- FEMY N/A
- HHS N/A
- EPS
- FEMY N/A
- HHS N/A
- Revenue
- FEMY $1,699,232.00
- HHS $181,355,000.00
- Revenue This Year
- FEMY $283.83
- HHS $6.54
- Revenue Next Year
- FEMY $161.03
- HHS N/A
- P/E Ratio
- FEMY N/A
- HHS N/A
- Revenue Growth
- FEMY 61.97
- HHS N/A
- 52 Week Low
- FEMY $0.69
- HHS $3.24
- 52 Week High
- FEMY $1.80
- HHS $8.49
- Technical
- Relative Strength Index (RSI)
- FEMY 47.01
- HHS 32.88
- Support Level
- FEMY $0.91
- HHS $3.37
- Resistance Level
- FEMY $0.99
- HHS $4.03
- Average True Range (ATR)
- FEMY 0.04
- HHS 0.28
- MACD
- FEMY 0.00
- HHS -0.02
- Stochastic Oscillator
- FEMY 22.33
- HHS 1.80
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.